Literature DB >> 32167394

Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes.

Jee Hee Yoo1,2, Min Sun Choi1, Jiyeon Ahn1, Sung Woon Park1, Yejin Kim1, Kyu Yeon Hur1, Sang-Man Jin1, Gyuri Kim1, Jae Hyeon Kim1.   

Abstract

Background: As the use of continuous glucose monitoring (CGM) has increased, time in range (TIR) and other core CGM metrics are now emerging as the core metrics for clinical targets and assessing diabetic complications, beyond HbA1c. This study investigated the association between the CGM-derived TIR, hyperglycemia, hypoglycemia metrics, and albuminuria.
Methods: A total of 866 subjects with type 2 diabetes who underwent 3 or 6 days of CGM and had urinary albumin-to-creatinine ratio (ACR) measurements were retrospectively reviewed. CGM metrics were defined according to the most recent international consensus. Albuminuria was defined as one or more of the ACR measurements being >30 mg/g.
Results: The overall prevalence of albuminuria was 36.6%. The prevalence of albuminuria was lower in subjects who achieved the target of TIR 70-180 mg/dL, time above range (TAR) >180 mg/dL, and TAR >250 mg/dL, as recommended by international consensus (P < 0.001). Multiple logistic regression analysis revealed that the odds ratio of having albuminuria was 0.94 (95% confidence interval: 0.88-0.99, P for trend = 0.04) per 10% increase in TIR of 70-180 mg/dL, after adjusting for multiple factors, including glycemic variability. The results were similar for hyperglycemia metrics (TAR >250 mg/dL and TAR >180 mg/dL). Conclusions: TIR 70-180 mg/dL and hyperglycemia metrics are strongly associated with albuminuria in type 2 diabetes.

Entities:  

Keywords:  Albuminuria; Continuous glucose monitoring; Microvascular complications; Time in range; Type 2 diabetes

Year:  2020        PMID: 32167394     DOI: 10.1089/dia.2019.0499

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  18 in total

1.  Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada.

Authors:  Stephane Roze; John J Isitt; Jayne Smith-Palmer; Peter Lynch
Journal:  Clinicoecon Outcomes Res       Date:  2021-08-11

2.  Clinical Application of Time in Range and Other Metrics.

Authors:  Grazia Aleppo
Journal:  Diabetes Spectr       Date:  2021-05-25

Review 3.  Time-in-range as a target in type 2 diabetes: An urgent need.

Authors:  Banshi Saboo; Jothydev Kesavadev; Arun Shankar; Meera B Krishna; Shruti Sheth; Vidisha Patel; Gopika Krishnan
Journal:  Heliyon       Date:  2021-01-15

4.  Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study.

Authors:  Norihiro Kuroda; Yoshiki Kusunoki; Keiko Osugi; Mana Ohigashi; Daisuke Azuma; Hiroki Ikeda; Shinya Makino; Akihito Otsuka; Daisuke Tamada; Nobuaki Watanabe; Kahori Washio; Taku Tsunoda; Toshihiro Matsuo; Kosuke Konishi; Tomoyuki Katsuno; Hidenori Koyama
Journal:  J Diabetes Investig       Date:  2020-08-02       Impact factor: 4.232

5.  Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review.

Authors:  Rishi Raj; Vivek Joshi; Rahul Mishra; Nivedita Jha; Ricardo Correa; Philip A Kern
Journal:  BMJ Open Diabetes Res Care       Date:  2022-01

6.  The Effectiveness of Traditional Chinese Medicine Jinlida Granules on Glycemic Variability in Newly Diagnosed Type 2 Diabetes: A Double-Blinded, Randomized Trial.

Authors:  Jiemin Pan; Yuejie Xu; Si Chen; Yinfang Tu; Yifei Mo; Fei Gao; Jian Zhou; Cheng Hu; Weiping Jia
Journal:  J Diabetes Res       Date:  2021-10-08       Impact factor: 4.011

7.  Beyond A1C-Standardization of Continuous Glucose Monitoring Reporting: Why It Is Needed and How It Continues to Evolve.

Authors:  Roy W Beck; Richard M Bergenstal
Journal:  Diabetes Spectr       Date:  2021-05-25

8.  Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol.

Authors:  Mana Ohigashi; Keiko Osugi; Yoshiki Kusunoki; Kahori Washio; Satoshi Matsutani; Taku Tsunoda; Toshihiro Matsuo; Kosuke Konishi; Tomoyuki Katsuno; Mitsuyoshi Namba; Hidenori Koyama
Journal:  J Diabetes Investig       Date:  2020-11-15       Impact factor: 4.232

9.  Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.

Authors:  Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Shinichiro Kawata; Hajime Sugawara; Jun Takeuchi; So Nagai; Kazuno Omori; Kazuhisa Tsuchida; Aika Miya; Ikumi Shigesawa; Kenichi Tsuchida; Shingo Yanagiya; Hiraku Kameda; Hiroki Yokoyama; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Naoki Nishimoto; Tatsuya Atsumi; Hideaki Miyoshi
Journal:  J Diabetes Investig       Date:  2021-02-05       Impact factor: 4.232

10.  Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial.

Authors:  Xiuzhen Zhang; Dan Xu; Ping Xu; Shufen Yang; Qingmei Zhang; Yan Wu; Fengyi Yuan
Journal:  Endocr Connect       Date:  2021-08-30       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.